145 related articles for article (PubMed ID: 19575225)
21. Evaluation of the Clinical Efficacy and Safety of a Spot-on Combination of Imidacloprid 10 % / Moxidectin 2.5 % (Advocate
Veronesi F; Di Cesare A; Braun G; Günther L; Morganti G; Rueca F; Petry G; Schaper R; Traversa D
Parasitol Res; 2017 Aug; 116(Suppl 1):65-74. PubMed ID: 28717949
[No Abstract] [Full Text] [Related]
22. Safety of imidacloprid plus moxidectin topical solution applied to cats heavily infected with adult heartworms (Dirofilaria immitis).
Arther RG; Atkins C; Ciszewski DK; Davis WL; Ensley SM; Settje TL
Parasitol Res; 2005 Oct; 97 Suppl 1():S70-S75. PubMed ID: 16228278
[TBL] [Abstract][Full Text] [Related]
23. The efficacy of a topically applied imidacloprid 10 % / moxidectin 2.5 % formulation (Advocate®, Advantage® Multi, Bayer) against Immature and Adult Spirocerca lupi worms in experimentally infected dogs.
Austin CM; Kok DJ; Crafford D; Schaper R
Parasitol Res; 2013 Aug; 112 Suppl 1():91-108. PubMed ID: 23779222
[TBL] [Abstract][Full Text] [Related]
24. Crenosoma vulpis in dog: first case report in Italy and use of the FLOTAC technique for copromicroscopic diagnosis.
Rinaldi L; Calabria G; Carbone S; Carrella A; Cringoli G
Parasitol Res; 2007 Nov; 101(6):1681-4. PubMed ID: 17805573
[TBL] [Abstract][Full Text] [Related]
25. Larvicidal effect of imidacloprid/moxidectin spot-on solution in dogs experimentally inoculated with Angiostrongylus vasorum.
Schnyder M; Fahrion A; Ossent P; Kohler L; Webster P; Heine J; Deplazes P
Vet Parasitol; 2009 Dec; 166(3-4):326-32. PubMed ID: 19800738
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of 10% imidacloprid + 2.5% moxidectin topical solution (Advantage Multi
Bowman DD; Ohmes CM; Hostetler JA; Keil DJ; Settje TL; Charles SD
Parasit Vectors; 2017 Nov; 10(Suppl 2):478. PubMed ID: 29143660
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of a combination of imidacloprid and moxidectin against parasites of reptiles and rodents: case reports.
Mehlhorn H; Schmahl G; Mevissen I
Parasitol Res; 2005 Oct; 97 Suppl 1():S97-S101. PubMed ID: 16228282
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of 10% imidacloprid+2.5% moxidectin for the treatment of Dirofilaria immitis circulating microfilariae in experimentally infected dogs.
McCall JW; Arther R; Davis W; Settje T
Vet Parasitol; 2014 Nov; 206(1-2):86-92. PubMed ID: 25444277
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the therapeutic and preventive efficacy of 2.5 % moxidectin / 10 % imidacloprid (Advocate(®), Bayer animal health) in dogs naturally infected or at risk of natural infection by Dirofilaria repens.
Hellmann K; Heine J; Braun G; Paran-Dobesova R; Svobodova V
Parasitol Res; 2011 Aug; 109 Suppl 1():S77-86. PubMed ID: 21739377
[TBL] [Abstract][Full Text] [Related]
30. Clinical, laboratory and pathological findings in dogs experimentally infected with Angiostrongylus vasorum.
Schnyder M; Fahrion A; Riond B; Ossent P; Webster P; Kranjc A; Glaus T; Deplazes P
Parasitol Res; 2010 Nov; 107(6):1471-80. PubMed ID: 20700604
[TBL] [Abstract][Full Text] [Related]
31. Treatment of canine generalized demodicosis associated with hyperadrenocorticism with spot-on moxidectin and imidacloprid.
Huang HP; Lien YH
Acta Vet Scand; 2013 May; 55(1):40. PubMed ID: 23663380
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Bravecto
Raue K; Rohdich N; Hauck D; Zschiesche E; Morelli S; Traversa D; Di Cesare A; Roepke RKA; Strube C
Parasit Vectors; 2021 Feb; 14(1):110. PubMed ID: 33593394
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of a spot on combination containing imidacloprid 10% and moxidectin 1% (Advocate(®)/Advantage(®) Multi, Bayer Animal Health) against Ancylostoma ceylanicum in cats.
Taweethavonsawat P; Chungpivat S; Watanapongchati S; Traub RJ; Schaper R
Vet Parasitol; 2012 Nov; 190(1-2):289-93. PubMed ID: 22677133
[TBL] [Abstract][Full Text] [Related]
34. Natural infections of Crenosoma vulpis and Angiostrongylus vasorum in dogs in Atlantic Canada and their treatment with milbemycin oxime.
Conboy G
Vet Rec; 2004 Jul; 155(1):16-8. PubMed ID: 15264484
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot-on in the treatment of generalized demodicosis in dogs: results of a European field study.
Heine J; Krieger K; Dumont P; Hellmann K
Parasitol Res; 2005 Oct; 97 Suppl 1():S89-S96. PubMed ID: 16228281
[TBL] [Abstract][Full Text] [Related]
36. Larvicidal and persistent efficacy of an imidacloprid and moxidectin topical formulation against endoparasites in cats and dogs.
von Samson-Himmelstjerna G; Epe C; Schimmel A; Heine J
Parasitol Res; 2003 Jul; 90 Suppl 3():S114-5. PubMed ID: 12928872
[No Abstract] [Full Text] [Related]
37. Infectivity of gastropod-shed third-stage larvae of Angiostrongylus vasorum and Crenosoma vulpis to dogs.
Robbins W; Conboy G; Greenwood S; Schaper R
Parasit Vectors; 2021 Jun; 14(1):307. PubMed ID: 34099050
[TBL] [Abstract][Full Text] [Related]
38. Elimination of Dirofilaria (syn. Nochtiella) repens microfilariae in dogs with monthly treatments of moxidectin 2.5%/imidacloprid 10% (Advocate, Bayer) spot-on.
Fok E; Jacsó O; Szebeni Z; Gyorffy A; Sükösd L; Lukács Z; Schaper R
Parasitol Res; 2010 Apr; 106(5):1141-9. PubMed ID: 20165873
[TBL] [Abstract][Full Text] [Related]
39. Protection of dogs against canine heartworm infection 28 days after four monthly treatments with Advantage Multi® for Dogs.
Bowman DD; Grazette AR; Basel C; Wang Y; Hostetler JA
Parasit Vectors; 2016 Jan; 9():12. PubMed ID: 26746229
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the Efficacy and Safety of an Imidacloprid 10 % / Moxidectin 1 % Spot-on Formulation (Advocate
Di Cesare A; Veronesi F; Capelli G; Deuster K; Schaper R; Basano FS; Nazzari R; Paoletti B; Traversa D
Parasitol Res; 2017 Aug; 116(Suppl 1):55-64. PubMed ID: 28717948
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
